Author:
van Hemert Formijn J.,Sloof Gerrit W.,Schimmel Kirsten J. M.,Vervenne Walter L.,van Eck-Smit Berthe L. F.,Busemann-Sokole Ellinor
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,General Medicine
Reference19 articles.
1. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanoulides C, Raubitschek A, et al. Radioimmuno- therapy of relapsed non-Hodgkin’s lymphoma with Zevalin, a90Y-labeled CD20 monoclonal antibody.Clin Cancer Res 1999;5:3281s-3286s.
2. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanoulides C, Raubitschek A, et al. Phase I/II trial of ZevalinTM (90yttrium ibritumomab tiuxetan; IDEC-Y2B8) radioimmunotherapy for treatment of relapsed or refractory CD20 positive B-cell non-Hodgkin’s lymphoma.J Clin Oncology 1999; 17: 3793–3803.
3. Juweid ME, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, Goldenberg DM. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with131I-labeled murine and humanized anti-carcinoembryonic antigen monoclonal antibodies.Gyneco Oncol 1997; 76: 259–271.
4. Juweid ME, Hajjar G, Swayne LC, Sharkey RM, Suleiman S, Hersko T, et al. Phase I/II trial of131I-MN-14(F(ab)2 anti- carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.Cancer 1999; 85: 1828–1842.
5. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14.Cancer 1993; 71: 2082–2096.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献